We came across a bullish thesis on Agios Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on AGIO. Agios Pharmaceuticals, Inc.'s share was trading at $27.80 as of January 15th. AGIO’s trailing and forward P/E were 3.54, respectively according to Yahoo Finance.
[caption id="attachment_995862" align="aligncenter" width="768"]Agios Pharmaceuticals is a clinical-stage biotech company focused on cellular metabolism through oral, small-molecule allosteric activators of the...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.